<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170705034918N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-09-09</date_registration>
      <primary_sponsor>Shahre-kord University of Medical Sciences</primary_sponsor>
      <public_title>The effect of herbal inhalation of Hydroalcoholic Extract of lavender, Coriandrum sativum, Zataria multiflora, Mentha piperita, in treatment of Sinus Headache</public_title>
      <acronym></acronym>
      <scientific_title>Clinical assessment of herbal inhalation of Hydroalcoholic Extract of lavender, Coriandrum sativum, Zataria multiflora, Mentha piperita, in treatment of Sinus Headache: A Randomized Double Blind Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/26558</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Stratified randomized collection will be done Based on age and gender; In such a way male and female patients will be assigned to the control and intervention group individually; and Randomization will be done by Random Allocation Software, Blinding description: Pharmaceutical and placebo products, with the same packaging, are categorized as A and B; And All phases of pharmaceutical formula  and placebo preparation are carried out by a pharmacognosit co-worker. it should be noted that researcher and also patients will not be informed of the contents of any products.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Sinus Headache.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group, every 8 hours, patients add 5 ml of the drug to 250 ml of boiling water and inhale the vapor of it for 15 minutes and the patients and researchers will not be aware of the contents of the drug and the placebo. The drug used in the intervention group contains a hydroalcoholic extracts of lavender, Coriandrum sativum, Zataria multiflora and Mentha piperita in a specified proportion according to the method mentioned in the British Pharmacopoeia, and the formulation will be prepared by the pharmacognostic colleagues. (Duration of the using drug  is 14 days). Intervention 2: In the control group, patients will be given placebo every 8 hours, they add 5 ml of the placebo to 250 ml of boiling water and inhale the vapor of it for 15 minutes and Duration of the using placebo is 14 days. The placebo contains a Food coloring with no active ingredient and the same as the original medicine will be designed and packaged so the patients and researchers will not be aware of the contents of the the placebo.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Personal information of patients is confidential.

When:
The beginning of the data access period is after collecting and analyzing them until the paper is published.

To whom:
Executor of plan

Conditions:
In order to analyze and review the results of the study

Where to obtain:
Executor of plan

How to obtain:
The Information is not given to people who are not responsible for the research.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza Heidari-soureshjani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kashani Blvd.</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8815894749</zip>
        <telephone>+98 38 3333 6539</telephone>
        <email>heidari.reza1995@gmail.com</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Zahra Lorigooini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kashani Blvd.</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۸۱۵۷۱۳۴۷۱</zip>
        <telephone>+98 38 3334 6692</telephone>
        <email>gueini.z@skmu.ac.ir</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People with a history of sinusitis assessed by the physician.
People with no history of migraine headaches.
People having at least three other symptoms of sinusitis such as nasal congestion.
People with pain in one or more than one sinuses.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>People who have ulcer in their mouth and nose.
People Having a history of allergy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J32</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic sinusitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group, every 8 hours, patients add 5 ml of the drug to 250 ml of boiling water and inhale the vapor of it for 15 minutes and the patients and researchers will not be aware of the contents of the drug and the placebo. The drug used in the intervention group contains a hydroalcoholic extracts of lavender, Coriandrum sativum, Zataria multiflora and Mentha piperita in a specified proportion according to the method mentioned in the British Pharmacopoeia, and the formulation will be prepared by the pharmacognostic colleagues. (Duration of the using drug  is 14 days)</i_keyword>
      <i_keyword>In the control group, patients will be given placebo every 8 hours, they add 5 ml of the placebo to 250 ml of boiling water and inhale the vapor of it for 15 minutes and Duration of the using placebo is 14 days. The placebo contains a Food coloring with no active ingredient and the same as the original medicine will be designed and packaged so the patients and researchers will not be aware of the contents of the the placebo.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Headaches. Timepoint: Before and two weeks after the intervention. Method of measurement: Based on VAS criteria.</prim_outcome>
      <prim_outcome>Rhinorrhea. Timepoint: Before and two weeks after the intervention. Method of measurement: Self-reported.</prim_outcome>
      <prim_outcome>Nasal congestion. Timepoint: Before and two weeks after the intervention. Method of measurement: Self-reported.</prim_outcome>
      <prim_outcome>Dyspnea. Timepoint: Before and two weeks after the intervention. Method of measurement: Self-reported.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahre-kord University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-07-01</approval_date>
        <contact_name>Ethics committee of shahrekord University of Medical Sciences</contact_name>
        <contact_address>Kashani Blvd, Shahrekord University of Medical Sciences Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
